J Hepatol
-
Publication Venue For
- Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.. 71:486-497. 2019
- Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.. 70:735-744. 2019
- Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.. 70:483-493. 2019
- Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.. 70:133-141. 2019
- The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.. 69:1365-1370. 2018
- Liver regeneration requires Yap1-TGFβ-dependent epithelial-mesenchymal transition in hepatocytes.. 69:359-367. 2018
- Towards a definite mouse model of NAFLD.. 69:272-274. 2018
- Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.. 68:1144-1152. 2018
- Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.. 68:1063-1075. 2018
- Hedgehog signalling in liver pathophysiology.. 68:550-562. 2018
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.. 67:263-271. 2017
- Iron overload in hereditary tyrosinemia type 1 induces liver injury through the Sp1/Tfr2/hepcidin axis.. 65:137-145. 2016
- Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency.. 64:370-379. 2016
- Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.. 64:29-36. 2016
- Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease.. 63:962-970. 2015
- Sugar sweetened beverages and fatty liver disease: Rising concern and call to action.. 63:306-308. 2015
- Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL).. 62:346-353. 2015
- Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.. 62:286-293. 2015
- A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.. 61:1238-1246. 2014
- Reply to: "depletion of hepatic stellate cells: have Kupffer cells lost their bad neighbor?".. 61:715-716. 2014
- Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.. 60:748-756. 2014
- A novel mouse model of depletion of stellate cells clarifies their role in ischemia/reperfusion- and endotoxin-induced acute liver injury.. 60:298-305. 2014
- Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis.. 58:778-784. 2013
- IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients.. 58:402-403. 2013
- Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.. 56:313-319. 2012
- Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo.. 55:1272-1280. 2011
- Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.. 55:1195-1200. 2011
- Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.. 55:1121-1131. 2011
- Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease.. 55:666-672. 2011
- Hedgehog signaling in the liver.. 54:366-373. 2011
- Microarchitecture of the liver: a jigsaw puzzle.. 54:187-188. 2011
- Liver transplantation for glycogen storage disease type Ia.. 51:483-490. 2009
- Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. 2017